Prevalence and associated factors of secondary hypogammaglobulinemia following rituximab therapy in a real-world cohort
Rituximab, an anti-CD20 monoclonal antibody, is widely used in the treatment of autoimmune and hematological diseases. However, its use has been associated with secondary hypogammaglobulinemia (SHG), a condition that may increase susceptibility to infections. The prevalence and clinical factors associated with SHG rema...